Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription.

Wang H, Lapek J, Fujimura K, Strnadel J, Liu B, Gonzalez DJ, Zhang W, Watson F, Yu V, Liu C, Melo CM, Miller YI, Elliott KC, Cheresh DA, Klemke RL.

Cell Discov. 2018 May 29;4:26. doi: 10.1038/s41421-018-0024-3. eCollection 2018.

2.

Re-thinking the preclinical development of GBM therapeutics.

Cosset É, Weis SM, Cheresh DA.

Oncoscience. 2018 Feb 23;5(1-2):11-12. doi: 10.18632/oncoscience.396. eCollection 2018 Jan. No abstract available.

3.

Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis.

Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier JS.

J Clin Invest. 2018 Jan 2;128(1):531-544. doi: 10.1172/JCI93707. Epub 2017 Dec 11.

4.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA.

Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub 2017 Nov 30.

PMID:
29198914
5.

Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.

Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh DA.

Cancer Discov. 2017 Dec;7(12):1464-1479. doi: 10.1158/2159-8290.CD-17-0539. Epub 2017 Sep 11.

PMID:
28893801
6.

Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy.

Hazell AS, Afadlal S, Cheresh DA, Azar A.

Neurosci Lett. 2017 Mar 6;642:163-167. doi: 10.1016/j.neulet.2017.01.041. Epub 2017 Jan 18.

PMID:
28109775
7.

MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment.

Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani SJ, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh DA, Anand S.

Nat Commun. 2016 Nov 25;7:13597. doi: 10.1038/ncomms13597.

8.

Kinase-independent role for CRAF-driving tumour radioresistance via CHK2.

Advani SJ, Camargo MF, Seguin L, Mielgo A, Anand S, Hicks AM, Aguilera J, Franovic A, Weis SM, Cheresh DA.

Nat Commun. 2015 Sep 3;6:8154. doi: 10.1038/ncomms9154.

9.

Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence.

Franovic A, Elliott KC, Seguin L, Camargo MF, Weis SM, Cheresh DA.

Cancer Res. 2015 Nov 1;75(21):4466-73. doi: 10.1158/0008-5472.CAN-15-0988. Epub 2015 Aug 21.

10.

hESC Differentiation toward an Autonomic Neuronal Cell Fate Depends on Distinct Cues from the Co-Patterning Vasculature.

Acevedo LM, Lindquist JN, Walsh BM, Sia P, Cimadamore F, Chen C, Denzel M, Pernia CD, Ranscht B, Terskikh A, Snyder EY, Cheresh DA.

Stem Cell Reports. 2015 Jun 9;4(6):1075-88. doi: 10.1016/j.stemcr.2015.04.013. Epub 2015 May 21.

11.

Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance.

Seguin L, Desgrosellier JS, Weis SM, Cheresh DA.

Trends Cell Biol. 2015 Apr;25(4):234-40. doi: 10.1016/j.tcb.2014.12.006. Epub 2015 Jan 5. Review.

12.

Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland.

Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A, Yebra M, Shattil SJ, Cheresh DA.

Dev Cell. 2014 Aug 11;30(3):295-308. doi: 10.1016/j.devcel.2014.06.005.

13.

Targeting the Achilles' heel of drug-resistant cancer stem cells.

Seguin L, Gozo M, Weis SM, Cheresh DA.

Cell Cycle. 2014;13(13):2017-8. doi: 10.4161/cc.29460. Epub 2014 Jun 6. No abstract available.

14.

Variety in the tumor microenvironment: integrin splicing regulates stemness.

Seguin L, Weis SM, Cheresh DA.

Cell Stem Cell. 2014 May 1;14(5):557-8. doi: 10.1016/j.stem.2014.04.011.

15.

An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA.

Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20.

16.

Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.

Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, Ward KK, Walsh CT, Miller NL, Ghassemian M, Turowski P, Dejana E, Weis S, Cheresh DA, Schlaepfer DD.

J Cell Biol. 2014 Jan 20;204(2):247-63. doi: 10.1083/jcb.201307067.

17.

Tumor angiogenesis: putting a value on plastic GEMMs.

Cheresh DA, Stupack DG.

Circ Res. 2014 Jan 3;114(1):9-11. doi: 10.1161/CIRCRESAHA.113.302812. No abstract available.

18.

A critical role for Lyn kinase in strengthening endothelial integrity and barrier function.

Han J, Zhang G, Welch EJ, Liang Y, Fu J, Vogel SM, Lowell CA, Du X, Cheresh DA, Malik AB, Li Z.

Blood. 2013 Dec 12;122(25):4140-9. doi: 10.1182/blood-2013-03-491423. Epub 2013 Oct 9.

19.

A wake-up call for hibernating tumour cells.

Weis SM, Cheresh DA.

Nat Cell Biol. 2013 Jul;15(7):721-3. doi: 10.1038/ncb2794.

PMID:
23817234
20.

PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes.

Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, Wang HY, Cheresh DA, Varner J.

Proc Natl Acad Sci U S A. 2013 May 28;110(22):9042-7. doi: 10.1073/pnas.1219603110. Epub 2013 May 13.

21.

Emerging Role of Micro-RNAs in the Regulation of Angiogenesis.

Anand S, Cheresh DA.

Genes Cancer. 2011 Dec;2(12):1134-8. doi: 10.1177/1947601911423032.

22.

Monographs editor.

Cheresh DA.

Genes Cancer. 2011 Dec;2(12):1071. doi: 10.1177/1947601911431886. No abstract available.

23.

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G.

Cancer Cell. 2012 Jul 10;22(1):21-35. doi: 10.1016/j.ccr.2012.05.037.

24.

Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression.

Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, Uryu S, Weis SM, Cheresh DA, Schlaepfer DD.

J Cell Biol. 2012 Jun 25;197(7):907-19. doi: 10.1083/jcb.201109067.

25.

EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.

Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA.

PLoS One. 2012;7(5):e36753. doi: 10.1371/journal.pone.0036753. Epub 2012 May 7.

26.

VEGF-induced vascular permeability is mediated by FAK.

Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD.

Dev Cell. 2012 Jan 17;22(1):146-57. doi: 10.1016/j.devcel.2011.11.002.

27.

αV integrins in angiogenesis and cancer.

Weis SM, Cheresh DA.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006478. doi: 10.1101/cshperspect.a006478. Review.

28.

Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane.

Scheppke L, Murphy EA, Zarpellon A, Hofmann JJ, Merkulova A, Shields DJ, Weis SM, Byzova TV, Ruggeri ZM, Iruela-Arispe ML, Cheresh DA.

Blood. 2012 Mar 1;119(9):2149-58. doi: 10.1182/blood-2011-04-348706. Epub 2011 Dec 1.

29.

A MEK-independent role for CRAF in mitosis and tumor progression.

Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA.

Nat Med. 2011 Nov 13;17(12):1641-5. doi: 10.1038/nm.2464.

30.

Tumor angiogenesis: molecular pathways and therapeutic targets.

Weis SM, Cheresh DA.

Nat Med. 2011 Nov 7;17(11):1359-70. doi: 10.1038/nm.2537. Review.

PMID:
22064426
31.

EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation.

Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA.

Oncogene. 2012 May 31;31(22):2783-93. doi: 10.1038/onc.2011.450. Epub 2011 Oct 3.

32.

A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.

Aspinall RJ, Weis SM, Barnes L, Lutu-Fuga K, Bylund DJ, Pockros PJ, Cheresh DA.

Liver Int. 2011 Sep;31(8):1222-30. doi: 10.1111/j.1478-3231.2011.02554.x. Epub 2011 Jun 7.

33.

Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY, Ohh M.

Nat Med. 2011 Jun 19;17(7):845-53. doi: 10.1038/nm.2370.

34.

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA.

Cancer Cell. 2011 Jun 14;19(6):715-27. doi: 10.1016/j.ccr.2011.04.016.

35.

Targeted nanogels: a versatile platform for drug delivery to tumors.

Murphy EA, Majeti BK, Mukthavaram R, Acevedo LM, Barnes LA, Cheresh DA.

Mol Cancer Ther. 2011 Jun;10(6):972-82. doi: 10.1158/1535-7163.MCT-10-0729. Epub 2011 Apr 25.

36.

MicroRNA-mediated regulation of the angiogenic switch.

Anand S, Cheresh DA.

Curr Opin Hematol. 2011 May;18(3):171-6. doi: 10.1097/MOH.0b013e328345a180. Review.

37.

Oncogenic Ras/Src cooperativity in pancreatic neoplasia.

Shields DJ, Murphy EA, Desgrosellier JS, Mielgo A, Lau SK, Barnes LA, Lesperance J, Huang M, Schmedt C, Tarin D, Lowy AM, Cheresh DA.

Oncogene. 2011 May 5;30(18):2123-34. doi: 10.1038/onc.2010.589. Epub 2011 Jan 17.

38.

MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis.

Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA.

Nat Med. 2010 Aug;16(8):909-14. doi: 10.1038/nm.2186. Epub 2010 Aug 1.

39.

Derivation of vasculature from embryonic stem cells.

Lindquist JN, Cheresh DA, Snyder EY.

Curr Protoc Stem Cell Biol. 2010 Mar;Chapter 1:Unit 1F.9. doi: 10.1002/9780470151808.sc01f09s12.

PMID:
20200855
40.

Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF.

Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh DA.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304. doi: 10.1073/pnas.0909299107. Epub 2010 Feb 12.

41.

RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia.

Shields DJ, Niessen S, Murphy EA, Mielgo A, Desgrosellier JS, Lau SK, Barnes LA, Lesperance J, Bouvet M, Tarin D, Cravatt BF, Cheresh DA.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2189-94. doi: 10.1073/pnas.0911646107. Epub 2009 Dec 28.

42.

Integrins in cancer: biological implications and therapeutic opportunities.

Desgrosellier JS, Cheresh DA.

Nat Rev Cancer. 2010 Jan;10(1):9-22. doi: 10.1038/nrc2748. Review.

43.

VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.

Greenberg JI, Cheresh DA.

Expert Opin Biol Ther. 2009 Nov;9(11):1347-56. doi: 10.1517/14712590903208883. Review.

PMID:
19761418
44.

An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.

Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ, Cheresh DA.

Nat Med. 2009 Oct;15(10):1163-9. doi: 10.1038/nm.2009. Epub 2009 Sep 6.

45.

Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation.

Koh W, Sachidanandam K, Stratman AN, Sacharidou A, Mayo AM, Murphy EA, Cheresh DA, Davis GE.

J Cell Sci. 2009 Jun 1;122(Pt 11):1812-22. doi: 10.1242/jcs.045799. Epub 2009 May 12.

46.

Agonizing integrin antagonists?

Weis SM, Stupack DG, Cheresh DA.

Cancer Cell. 2009 May 5;15(5):359-61. doi: 10.1016/j.ccr.2009.04.005.

47.

Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis.

Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK, Cheresh DA.

Cancer Res. 2009 Feb 15;69(4):1383-91. doi: 10.1158/0008-5472.CAN-08-3612. Epub 2009 Feb 10.

48.

Suppressing NFAT increases VEGF signaling in hemangiomas.

Acevedo LM, Cheresh DA.

Cancer Cell. 2008 Dec 9;14(6):429-30. doi: 10.1016/j.ccr.2008.11.009.

49.

Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.

Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA.

J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. doi: 10.1124/jpet.108.144311. Epub 2008 Dec 4.

50.

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.

Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS.

Nature. 2008 Dec 11;456(7223):814-8. doi: 10.1038/nature07445. Epub 2008 Nov 9.

Supplemental Content

Loading ...
Support Center